Heather Losey, Ph.D.

Heather Losey obtained her Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard Medical School in the laboratory of Chris Walsh, studying glycosyltransferases involved in the biosynthesis of vancomycin-type antibiotics. She then moved to do a postdoc at Harvard Department of Chemistry and Chemical Biology in the laboratory of Greg Verdine, focusing on the crystal structure and mechanism of tRNA adenosine deaminases. Losey joined Wyeth in 2006, focused on small and large molecule drug discovery in metabolic diseases and hemophilia research. While at Wyeth/Pfizer, her interest in protein engineering and protein structure-function took hold while working on design of next-generation coagulation factor proteases. In 2011, she moved to Alkermes in Waltham, MA helping to build the protein therapeutics program. While at Alkermes, she led the protein engineering efforts in immunology and cancer immunotherapy, including ALKS 4230, for which she has been involved from the inception through to the current Phase I/II clinical trials.